Literature DB >> 12539063

Epidemic Rift Valley fever in Saudi Arabia: a clinical study of severe illness in humans.

Mohammed Al-Hazmi1, Ephraim Ayobanji Ayoola, Mahmoud Abdurahman, Subodh Banzal, Jammal Ashraf, Adil El-Bushra, Ali Hazmi, Mohammed Abdullah, Hamid Abbo, Abdulhadi Elamin, El-Tayeb Al-Sammani, Mohammed Gadour, Chandra Menon, Mirghani Hamza, Inam Rahim, Magdy Hafez, Manish Jambavalikar, Haider Arishi, Ali Aqeel.   

Abstract

We describe the clinical patterns and case-fatality rate associated with severe Rift Valley fever (RVF) in patients who were admitted to the Gizan regional referral hospital during an outbreak of RVF in Saudi Arabia from September through November 2000. A total of 165 consecutive patients (136 men and 29 women) were prospectively studied; all were identified according to a strict case definition, were confirmed to have RVF by serologic testing, and were treated according to a predetermined protocol. The major clinical characteristics of RVF included a high frequency of hepatocellular failure in 124 patients (75.2%), acute renal failure in 68 patients (41.2%), and hemorrhagic manifestations in 32 patients (19.4%). Sixteen patients had retinitis and 7 patients had meningoencephalitis as late complications in the course of the disease. A total of 56 patients (33.9%) died. Hepatorenal failure, shock, and severe anemia were major factors associated with patient death.

Entities:  

Mesh:

Year:  2003        PMID: 12539063     DOI: 10.1086/345671

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  82 in total

1.  Epidemiologic and clinical aspects of a Rift Valley fever outbreak in humans in Tanzania, 2007.

Authors:  Mohamed Mohamed; Fausta Mosha; Janeth Mghamba; Sherif R Zaki; Wun-Ju Shieh; Janusz Paweska; Sylvia Omulo; Solomon Gikundi; Peter Mmbuji; Peter Bloland; Nordin Zeidner; Raphael Kalinga; Robert F Breiman; M Kariuki Njenga
Journal:  Am J Trop Med Hyg       Date:  2010-08       Impact factor: 2.345

2.  Creation of a nonspreading Rift Valley fever virus.

Authors:  Jeroen Kortekaas; Nadia Oreshkova; Viviana Cobos-Jiménez; Rianka P M Vloet; Christiaan A Potgieter; Rob J M Moormann
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

3.  Vascular permeability in the brain is a late pathogenic event during Rift Valley fever virus encephalitis in rats.

Authors:  Aaron W Walters; Michael R Kujawa; Joseph R Albe; Douglas S Reed; William B Klimstra; Amy L Hartman
Journal:  Virology       Date:  2018-11-02       Impact factor: 3.616

Review 4.  Emerging infectious diseases: the Bunyaviridae.

Authors:  Samantha S Soldan; Francisco González-Scarano
Journal:  J Neurovirol       Date:  2005-10       Impact factor: 2.643

5.  Sequential Rift Valley fever outbreaks in eastern Africa caused by multiple lineages of the virus.

Authors:  Leonard Nderitu; John S Lee; Jared Omolo; Sylvia Omulo; Monica L O'Guinn; Allen Hightower; Fausta Mosha; Mohamed Mohamed; Peninah Munyua; Zipporah Nganga; Kelli Hiett; Bruce Seal; Daniel R Feikin; Robert F Breiman; M Kariuki Njenga
Journal:  J Infect Dis       Date:  2010-12-14       Impact factor: 5.226

6.  Using a field quantitative real-time PCR test to rapidly identify highly viremic rift valley fever cases.

Authors:  M Kariuki Njenga; Janusz Paweska; Rose Wanjala; Carol Y Rao; Matthew Weiner; Victor Omballa; Elizabeth T Luman; David Mutonga; Shanaaz Sharif; Marcus Panning; Christian Drosten; Daniel R Feikin; Robert F Breiman
Journal:  J Clin Microbiol       Date:  2009-01-26       Impact factor: 5.948

Review 7.  Recent advances in the development of antiviral therapeutics for Rift Valley fever virus infection.

Authors:  Colm Atkins; Alexander N Freiberg
Journal:  Future Virol       Date:  2017-10-23       Impact factor: 1.831

8.  A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity.

Authors:  David H Holman; Adam Penn-Nicholson; Danher Wang; Jan Woraratanadharm; Mary-Katherine Harr; Min Luo; Ellen M Maher; Michael R Holbrook; John Y Dong
Journal:  Clin Vaccine Immunol       Date:  2009-09-23

9.  Rift Valley Fever among febrile patients at New Halfa hospital, eastern Sudan.

Authors:  Ahmed M Hassanain; Waleed Noureldien; Mubarak S Karsany; El Najeeb S Saeed; Imadeldin E Aradaib; Ishag Adam
Journal:  Virol J       Date:  2010-05-13       Impact factor: 4.099

10.  A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge.

Authors:  Robert B Mandell; Ramesh Koukuntla; Laura J K Mogler; Andrea K Carzoli; Alexander N Freiberg; Michael R Holbrook; Brian K Martin; William R Staplin; Nicholas N Vahanian; Charles J Link; Ramon Flick
Journal:  Virology       Date:  2009-11-24       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.